A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

New England Journal of Medicine

Volumn 383, Issue 6, 2020, Pages 517-525

  Boulware, David R ^a   Pullen, Matthew F ^a   Bangdiwala, Ananta S ^a   Pastick, Katelyn A ^a   Lofgren, Sarah M ^d   Okafor, Elizabeth C ^a   Skipper, Caleb P ^a   Nascene, Alanna A ^a   Nicol, Melanie R ^a   Abassi, Mahsa ^a   Engen, Nicole W ^a   Cheng, Matthew P ^c   Labar, Derek ^b   Lother, Sylvain A ^a   Mackenzie, Lauren J ^d   Drobot, Glen ^d   Marten, Nicole ^d   Zarychanski, Ryan ^d   Kelly, Lauren E ^e   Schwartz, Ilan S ^f   Mcdonald, Emily G ^c   Rajasingham, Radha ^a   Lee, Todd C ^c   Hullsiek, Kathy H ^a   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b Fairview Pharmacy Services LLC   (United States)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

^e Manitoba SPOR SUPPORT Unit   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Coronavirus; Global Health; Infectious Disease; Infectious Disease General; Viral Infections

Indexed keywords

HYDROXYCHLOROQUINE;

ADULT; BETACORONAVIRUS; CANADA; CLINICAL TRIAL; CONTROLLED STUDY; CORONAVIRUS INFECTION; DOUBLE BLIND PROCEDURE; EXPOSURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; OCCUPATIONAL EXPOSURE; PANDEMIC; POST EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; UNITED STATES; VIRUS PNEUMONIA;

ADULT; BETACORONAVIRUS; CANADA; CORONAVIRUS INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INHALATION EXPOSURE; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PANDEMICS; PNEUMONIA, VIRAL; POST-EXPOSURE PROPHYLAXIS; TREATMENT FAILURE; UNITED STATES;

EID: 85086854352     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa2016638     Document Type: Article

References (18)

1. 1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199-207.
2. 2. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69.
3. 3. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 March 9 (Epub ahead of print).
4. 4. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARSCoV-2 infection in vitro. Cell Discov 2020; 6: 16.
5. 5. Pastick KA, Okafor EC, Wang F, et al. Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect Dis 2020; 7: Ofaa130.
6. 6. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 382:2411-8.
7. 7. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet 2020 May 22 (Epub ahead of print).
8. 8. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020 May 11 (Epub ahead of print).
9. 9. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19-United States, January-February 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 245-6.
10. 10. Park SY, Kim YM, Yi S, et al. Coronavirus disease outbreak in call center, South Korea. Emerg Infect Dis 2020 April 23 (Epub ahead of print).
11. 11. Lee SH, Son H, Peck KR. Can postexposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? Int J Antimicrob Agents 2020 April 17 (Epub ahead of print).
12. 12. Lother SA, Abassi M, Agostinis A, et al. Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Study protocol for a pragmatic randomizedcontrolled trial. Can J Anaesth 2020 May 7 (Epub ahead of print).
13. 13. Harris PA, Taylor R, Minor BL, et al. The REDCap Consortium: Building an international community of software platform partners. J Biomed Inform 2019; 95: 103208.
14. 14. Al-Kofahi M, Jacobson P, Boulware DR, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther 2020 April 28 (Epub ahead of print).
15. 15. Council of State and Territorial Epidemiologists. Interim-20-ID-01: Standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19). 2020 (https://www.cste.org/resource/resmgr/2020ps/Interim-20-ID-01-COVID-19.pdf).
16. 16. McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a longterm care facility in King County, Washington. N Engl J Med 2020; 382: 2005-11.
17. 17. CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19-United States, February 12-April 9, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 477-81.
18. 18. Centers for Disease Control and Prevention. FAQ: COVID-19 data and surveillance. 2020 (https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html).